<DOC>
	<DOCNO>NCT00094705</DOCNO>
	<brief_summary>Dengue fever , cause dengue virus , major health problem tropical subtropical region world . The purpose study test safety immune response new dengue virus vaccine healthy adult .</brief_summary>
	<brief_title>Safety Immune Response Dengue Virus Vaccine ( rDEN2/4delta30ME ) Healthy Adults</brief_title>
	<detailed_description>Dengue virus cause dengue fever , well severe dengue hemorrhagic fever/shock syndrome . More 2 billion people live tropical subtropical region world risk dengue virus infection , lead cause hospitalization death child several tropical Asian country . This study evaluate safety immunogenicity live attenuate dengue virus vaccine call rDEN2/4delta30 ( ME ) , derive DEN2 DEN4 serotypes . This study last 180 day . Participants Cohort 1 randomly assign receive rDEN2/4delta30 ( ME ) placebo study entry . Cohort 2 begin safety review participant Cohort 1 . Participants Cohort 2 receive high dose rDEN2/4delta30 ( ME ) placebo . After vaccination , participant observe least 30 minute immediate adverse reaction . Participants also ask monitor temperature every day 16 day . Study visit occur every day vaccination Day 16 , follow 4 additional visit select day Day 180 . Blood collection target physical exam occur study visit . Some participant ask undergo skin biopsy additional blood collection select visit .</detailed_description>
	<mesh_term>Dengue</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Willing follow duration study Willing use acceptable method contraception Good general health Clinically significant neurologic , cardiac , pulmonary , hepatic , rheumatologic , autoimmune , renal disease Behavioral , cognitive , psychiatric disease , opinion investigator , affect ability volunteer understand cooperate study Hematologic disease Alcohol drug abuse within 12 month prior study entry History severe allergic reaction anaphylaxis Emergency room visit hospitalization severe asthma within 6 month prior study entry HIV1 infect Hepatitis C virus infect Hepatitis B surface antigen positive Known immunodeficiency syndrome Use corticosteroid immunosuppressive drug within 30 day prior study entry . Participants use topical nasal corticosteroid exclude . Live vaccine within 4 week prior study entry Killed vaccine within 2 week prior study entry Blood product within 6 month prior study entry Participation another investigational vaccine drug trial within 60 day start study , trial ongoing Previously receive licensed experimental yellow fever dengue vaccine Surgical removal spleen History dengue virus infection flavivirus infection ( e.g. , yellow fever virus , St. Louis encephalitis , West Nile virus , Japanese encephalitis virus ) Other condition , opinion investigator , would affect participant 's participation study Plan travel area dengue infection common Pregnancy breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Dengue Vaccine</keyword>
	<keyword>Dengue Virus</keyword>
	<keyword>Dengue Hemorrhagic Fever</keyword>
	<keyword>Dengue Shock Syndrome</keyword>
</DOC>